The 6th Annual meeting of Mongolian Nephrology Association 2025

The 6th Annual Meeting of the Mongolian Nephrology Association 2025 was held on November 22 in Ulaanbaatar and became a significant event for the country’s medical professional community, bringing together more than 85 nephrologists and specialists from all provinces and the capital. The full-day program included up-to-date scientific data, educational sessions, and presentations on the latest advancements in nephrology. The Congress was organized by the Mongolian Nephrology Association in cooperation with the Mongolian National University of Medical Sciences (MNUMS) and the MNUMS Mongolia–Japan Hospital.

Alpen Pharma proudly participated in this key industry event by presenting Solidagoren, Dannosa Uro-Akut, and Dannosa Uro-Prolong. During the exhibition session, healthcare professionals had the opportunity to learn more about the high quality of our products, their proven clinical benefits, and up-to-date evidence supporting their effectiveness. Specialists highlighted the high level of expertise demonstrated by the Alpen Pharma team and the value of the information provided.

Particular interest from physicians was directed toward the Dannosa product line, reflecting the growing demand for innovative D-mannose–based solutions. This interest further increased following the recent update of the clinical guidelines of the National First Central Hospital, which for the first time introduced a recommendation to integrate D-mannose–containing products into therapeutic practice. This development significantly strengthened attention to Alpen Pharma’s portfolio and emphasized its relevance in modern clinical workflows.

Among the four pharmaceutical companies participating in the exhibition and presentation program, Alpen Pharma’s products became some of the most discussed and well-received. This strong level of engagement reinforces the company’s confident market position and highlights the brand’s growth potential in Mongolia.

The results of the Congress demonstrate increasing trust from the medical community and a rising interest in Alpen Pharma’s solutions, especially the Dannosa series. The company sees strong prospects for expanding collaboration with nephrologists across Mongolia and remains committed to promoting modern, evidence-based therapeutic approaches that help improve patient quality of life.